H. Lee Moffitt Cancer Center & Research Institute

Overview

Specialized Program in Research Excellence (SPORE) in Lung Cancer

Lung cancer is the leading cause of cancer death for men and women. The state of Florida is second behind California in the number of new lung cancer cases per year.  In the fall of 2008 the National Cancer Institute (NCI) awarded Dr. Gerold Bepler, program leader for thoracic oncology at Moffitt Cancer Center, and his team a Specialized Programs of Research Excellence (SPORE) grant in lung cancer. The grant totals $10,475,090 over five years.

SPORE Sponsored Translational Research

Moffitt will conduct four primary research projects as follows (click here for publications related to these projects):

• E2Fs impact on therapeutic efficacy:  Douglas Cress, Ph.D., Jiandong Chen, Ph.D., and Gerold Bepler, M.D., Ph.D
• Antitumor mechanism of src inhibitors:  Eric Haura, M.D., Jin Cheng, M.D., Ph.D., and Jack Pledger, Ph.D.
• Chemoprevention with enzasataurin:  Gerold Bepler, M.D., Ph.D and Mark Alexandrow, Ph.D.
• P53-based vaccine for small cell lung cancer:  Dmitry Gabrilovich, M.D., Ph.D. and Scott Antonia, M.D., Ph.D.

In addition, the SPORE in Lung Cancer provides funding for developmental research projects in lung cancer research.  Click here for a current listing of developmental projects.  In addition, the SPORE funds career development awards for promising investigators seeking to develop or strengthen programs in lung cancer research.   The deadline to apply for a career development award is Nov 1, 2008.  Contact Carol Ulge (carol.ulge@moffitt.org) for more information about career development funds and how to apply.